menu

Quintiles Library

Show Filters
White Paper
Recruitment of a sufficiently large number of participants into clinical trials can be a challenge in multiple therapeutic areas, and this has become particularly true for multiple sclerosis trials. For many reasons, the protocols for these trials have become very complex, and hence demanding on participants. A central difficulty in recruitment is identifying eligible...
Explore More
Infographic
Extraordinary discoveries are transforming the approach to cancer care – and immunotherapy is one of the most promising avenues of research. QuintilesIMS identifies the top 5 challenges in executing immune-oncology clinical trials, and innovative solutions to address those needs.
Read More
White Paper
This insight brief examines the shift of regulatory affairs work to local hubs, which is creating new opportunities for regulatory professionals to work directly with regulators, provide thought leadership input within their respective organizations, and support product development, while leveraging new technologies. Based on market leadership with over 7,000 product...
Explore More
White Paper
The E2B(R2) standard was first adapted in February 2001. Since then, many changes have been made across the countries where it applies. These changes have promoted an update to E2B(R2) with the new E2B(R3) - which will have a major impact on pharmacovigilance systems and processes, particularly on adverse event reporting and collection of data on drugs. Based on...
Explore More
Article
PharmaBoardroom Q&A with Anand Tharmaratnam, President of QuintilesIMS Asia Pacific, about life-sciences in Asia Pac and Singapore's role as a hub for the region.
Explore More
Presentation
Over the past 30 years, our greatest accomplishments in advancing understanding about the safety, effectiveness and value of healthcare interventions have been achieved through the studying of health records for large populations. More recently, access to electronic health records and other electronic data that can be linked or supplemented by other critical information...
Explore More
Presentation
Risk-based monitoring, and its increasing awareness, is widely viewed as a clinical strategy contributing to better quality control, data accuracy and lower costs. The core of risk-based monitoring is Centralized Monitoring, which has evolved through three stages or “waves,” with value increasing at each wave. QuintilesIMS has built and recently launched a technology...
Explore More
White Paper
The dramatic increase in the amount of digitized healthcare information being generated brings new opportunity to close the “healthcare gap” – the difference between today’s reality and what is possible from a clinical, patient and economic perspective. Appropriately accessing and utilizing information for research purposes is a critical element of closing this gap. In...
Explore More
White Paper
Risk-based monitoring, and its increasing awareness, is widely viewed as a clinical strategy contributing to better quality control, data accuracy and lower costs. The core of risk-based monitoring is Centralized Monitoring, which has evolved through three stages or “waves,” with value increasing at each wave. QuintilesIMS has built and recently launched a technology...
Explore More
Infographic
QuintilesIMS Continuous Glucose Monitoring offers a more complete view of the daily measures of glucose levels and variability than the traditional measures of glucose control by self-monitored blood glucose (SMBG) and HbA1c, promoting enhanced patient safety and clinical outcomes. Our innovative platform – combined with leading operational and therapeutic expertise –...
Read More
White Paper
下一代测序技术将为肿瘤临床试验和癌症治疗带来革新
Explore More
Fact Sheet
QuintilesIMS Solution Design Studio offers an interactive, visual approach to defining and designing technology solutions. By allowing your stakeholders to experience proposed solutions from the beginning, we can envision optimal outcomes together. Digital simulation, user interface design and proven early-development process help drive on-target innovation and rapid...
Read More
White Paper
This insight brief examines the varied definitions and regulatory pathways for rare disease therapies. The authors describe QuintilesIMS’s proven patient centric approaches to study planning, innovative ways to accelerate patient recruitment through an efficient site strategy, and the importance of real-world evidence.
Explore More
Brochure
Getting a drug through clinical trials and successfully on to the market after regulatory approval is a long process, and it might be understandable for a company to metaphorically take a moment to catch its breath. Approval, however, is only the first step; the next big hurdle is to get the best positioning and market access for the drug, so that the right patients can...
Read More
Brochure
Managing long term conditions is challenging, for both patients and the healthcare system. Getting patients more involved in their care through patient support programs can help improve their outcomes and take the pressure off the healthcare system. Gain an understanding of why programs need to be tailored specifically to the patient, disease type and its stage. Learn...
Read More
White Paper
The future of medicine rests on data: the evidence that is the basis for the discovery, development and dispensing of prescription products and all other healthcare decisions. Data, and the analysis of that data, informs drug development, portfolio decisions, prescribing behaviors, patient compliance and reimbursement policy in value-based healthcare systems. Mastering...
Explore More
White Paper
Multiple myeloma is an extremely complex genomic disease that accounts for 1% of all cancers and 13% of all hematologic malignancies. Worldwide, approximately 86,000 new cases occur annually. Recently, clinical research in multiple myeloma has been very active, and various novel therapies are being investigated. This White Paper addresses several important components of...
Explore More
Fact Sheet
For success in early clinical development, it’s critical to find the right participants, target dose/exposure, response and commercial strategy. A tailored delivery model that is proactive and scalable can help you meet these challenges – and accelerate your Phase I trial or program. Improve your probability of success with QuintilesIMS’s global drug development...
Read More
Presentation
Today’s diabetes clinical development landscape is competitive, complex, and in demand. Continuous Glucose Monitoring (CGM) has the potential to become the new gold-standard in diabetes clinical trials. CGM provides more robust glycemic data sets and glucose variability than ever before, which leads to better clinical outcomes and patient safety. Navigating and...
Explore More
Presentation
Drug development challenges drive the need to translate scientific and therapeutic advances to better outcomes. As such, developing the evidence you need to meet the needs of all stakeholders, including investors, regulators, payers, providers and patients, and proving value in the real-world becomes critical.In this webinar, QuintilesIMS experts Laura Marquis, John Doyle...
Explore More